(24/7 MARKET NEWS) – Vapotherm, Inc. (NASDAQ:VAPO) reported, this morning, the presentation of an Investigator-initiated clinical trial, “High flow humidified oxygen as an early intervention in children with acute severe asthma – a feasibility randomized controlled trial” at the European Respiratory Society International Congress 2023, conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England. Children who presented to the Emergency Department with acute, severe, asthma exacerbations that did not respond to initial pharmacologic treatment were randomized to either HVNI or standard nasal oxygen therapy. Eighty-six percent (19/22) of children treated with standard oxygen required escalation of therapy, while only 61% (17/28) of children treated with HVNI needed further escalation. Additionally, children treated with HVNI met hospital discharge criteria in a median time of 29 hours, compared to a median time of 37 hours for those treated with standard oxygen.
Vapotherm is trading at $2.72, up $0.26 (+10.56%), on 3.3K premarket shares traded.
Its 52-week range is $2.34 to $23.44. It needs a volume jolt to make a meaningful move.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.